Dr Reddy's labs gets USFDA 3 observations for New York API facility

Published On 2021-03-11 06:51 GMT   |   Update On 2021-03-11 06:51 GMT
Advertisement

New Delhi: Dr Reddy's Laboratories on Wednesday said the US health regulator has issued a Form 483 with three observations after inspecting its manufacturing facility in Middleburg, New York. The audit of the company's active pharmaceutical ingredients (API) manufacturing plant at Middleburg, New York has been completed by the US Food and Drug Administration (USFDA), the Hyderabad-based drug major said in a regulatory filing.

"We have been issued a Form 483 with 3 (three) observations. We will address them comprehensively within the stipulated timeline. Currently, we do not have any sales from this plant," it added.
As per the USFDA, Form 483 is issued to firm management at the conclusion of an inspection when investigators have observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic Act and related acts.


Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News